Table 6.6a

Immunosuppression Use for Induction, 1997 to 2006

Recipients with Pancreas Transplant Alone (PTA) Transplants

  Year of Transplant
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Transplants 79 88 139 134 167 180 158 182 198 169
With Immunosuppression Info 76 80 136 128 165 177 153 176 193 165
Induction Drugs 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ALG
Atgam/NRATG/NRATS 18.4% 15.0% 8.1% 0.0% 0.0% 0.0% 1.3% 2.3% 0.0% 0.6%
OKT3 39.5% 22.5% 7.4% 4.7% 3.0% 2.8% 0.7% 0.0% 2.1% 5.5%
Thymoglobulin 0.0% 0.0% 30.1% 48.4% 49.1% 59.9% 45.1% 51.1% 48.2% 42.4%
Zenapax 1.3% 31.3% 30.1% 44.5% 34.5% 31.1% 7.8% 9.7% 5.2% 10.9%
Simulect 0.0% 3.8% 11.0% 9.4% 3.0% 4.0% 6.5% 0.0% 2.1% 2.4%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 1.1% 32.0% 42.0% 33.7% 24.2%
No Induction Drugs Recorded 40.8% 41.3% 37.5% 29.7% 38.8% 30.5% 18.3% 18.8% 16.6% 20.0%


Source: OPTN/SRTR Data as of May 1, 2007.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.